Artiva Biotherapeutics (ARTV) Net Cash Flow (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Net Cash Flow for 4 consecutive years, with -$5.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 40.34% year-over-year to -$5.7 million; the TTM figure through Mar 2026 stood at -$9.5 million (up 40.58% YoY), while the FY2025 annual figure was -$13.4 million, down 0.84% from the prior year.
• Net Cash Flow slipped to -$5.7 million in Q1 2026 per ARTV's latest filing, from $1.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $21.6 million in Q3 2024 and bottomed at -$15.6 million in Q4 2024.
• Historically, Net Cash Flow has averaged -$2.8 million across 4 years, with a median of -$5.3 million in 2024.
• On a YoY basis, Net Cash Flow climbed as much as 107.31% in 2025 and fell as far as 113.68% in 2025.
• Artiva Biotherapeutics' Net Cash Flow stood at -$12.4 million in 2023, then declined by 26.37% to -$15.6 million in 2024, then surged by 107.31% to $1.1 million in 2025, then slumped by 602.27% to -$5.7 million in 2026.
• Business Quant data shows ARTV's Net Cash Flow at -$5.7 million in Q1 2026, $1.1 million in Q4 2025, and -$3.0 million in Q3 2025.